JP2005506516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506516A5 JP2005506516A5 JP2002562209A JP2002562209A JP2005506516A5 JP 2005506516 A5 JP2005506516 A5 JP 2005506516A5 JP 2002562209 A JP2002562209 A JP 2002562209A JP 2002562209 A JP2002562209 A JP 2002562209A JP 2005506516 A5 JP2005506516 A5 JP 2005506516A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- stimuli
- stress
- value
- pituitary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 claims description 50
- 210000003296 Saliva Anatomy 0.000 claims description 49
- 241000124008 Mammalia Species 0.000 claims description 48
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 41
- 230000002618 waking Effects 0.000 claims description 41
- 239000003246 corticosteroid Substances 0.000 claims description 35
- 230000001953 sensory Effects 0.000 claims description 28
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims description 26
- 229960001334 Corticosteroids Drugs 0.000 claims description 26
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 22
- 230000001919 adrenal Effects 0.000 claims description 20
- 230000001817 pituitary Effects 0.000 claims description 19
- 210000003016 Hypothalamus Anatomy 0.000 claims description 15
- 230000003042 antagnostic Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000001603 reducing Effects 0.000 claims description 11
- 230000000007 visual effect Effects 0.000 claims description 10
- 230000001339 gustatory Effects 0.000 claims description 9
- 230000003340 mental Effects 0.000 claims description 9
- 230000002267 hypothalamic Effects 0.000 claims description 8
- 230000001965 increased Effects 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 3
- 230000001430 anti-depressive Effects 0.000 claims 6
- 239000000935 antidepressant agent Substances 0.000 claims 6
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 claims 1
- 210000001103 Thalamus Anatomy 0.000 claims 1
- 230000035882 stress Effects 0.000 description 111
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 57
- 229960000890 hydrocortisone Drugs 0.000 description 57
- 238000005259 measurement Methods 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- 239000003205 fragrance Substances 0.000 description 16
- 230000003247 decreasing Effects 0.000 description 12
- 230000002829 reduced Effects 0.000 description 11
- 230000000875 corresponding Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 229940088597 Hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 210000004404 Adrenal Cortex Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- -1 baths Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 3
- 102100008873 POMC Human genes 0.000 description 3
- 108060006375 POMC Proteins 0.000 description 3
- 230000001780 adrenocortical Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002438 stress hormone Substances 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 240000004119 Melissa officinalis Species 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 229940053479 Selective serotonin reuptake inhibitors Drugs 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 206010040984 Sleep disease Diseases 0.000 description 2
- 102000014034 Transcortin Human genes 0.000 description 2
- 108010011095 Transcortin Proteins 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000003542 behavioural Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001506 immunosuppresive Effects 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 231100000533 low birth weight Toxicity 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002889 sympathetic Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000000700 tracer Substances 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 229940035620 ACTH and synthetic analog preparations Drugs 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 210000001943 Adrenal Medulla Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 210000003792 Cranial Nerves Anatomy 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229960002464 Fluoxetine Drugs 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 1
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 1
- 235000016247 Mentha requienii Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 210000001640 Nerve Endings Anatomy 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 241000287463 Phalacrocorax Species 0.000 description 1
- 210000003635 Pituitary Gland Anatomy 0.000 description 1
- 210000001369 Pituitary-Adrenal System Anatomy 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 229940035613 Prozac Drugs 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 210000004911 Serous fluid Anatomy 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 210000003371 Toes Anatomy 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 108010036141 alpha helical corticotropin-releasing hormone Proteins 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108010063987 astressin Proteins 0.000 description 1
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000006682 bigleaf mint Nutrition 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000001914 calming Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000035591 circadian rhythms Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 235000006679 mint Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000037327 stress response Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25681200P | 2000-12-20 | 2000-12-20 | |
| US10/012,626 US20020090664A1 (en) | 2000-12-20 | 2001-12-07 | Methods for measuring stress in mammals |
| PCT/US2001/050220 WO2002062198A2 (en) | 2000-12-20 | 2001-12-20 | Methods for measuring stress in mammals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506516A JP2005506516A (ja) | 2005-03-03 |
| JP2005506516A5 true JP2005506516A5 (US20070275102A9-20071129-P00001.png) | 2007-09-06 |
Family
ID=26683803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002562209A Pending JP2005506516A (ja) | 2000-12-20 | 2001-12-20 | 哺乳類動物におけるストレスを測定するための方法 |
Country Status (7)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1218023B8 (en) | 1999-10-01 | 2006-05-03 | Johnson & Johnson Consumer Companies, Inc. | Method for calming human beings using personal care compositions |
| FR2831821B1 (fr) * | 2001-11-06 | 2004-01-09 | Ar2I Sa Analyses Rech S Et Inn | Marqueur biologique des etats de stress, procede d'evaluation quantitative de presence de ce marqueur, et son utilisation pour la prevention du stress |
| GB0203045D0 (en) * | 2002-02-08 | 2002-03-27 | Johnson & Johnson Consumer | Method of afefecting sleep and sleep-related behaviours |
| US6833274B2 (en) * | 2002-05-28 | 2004-12-21 | The Johns Hopkins University | Cortisol sensor |
| KR20060090974A (ko) * | 2003-09-05 | 2006-08-17 | 가부시키가이샤 시세이도 | 온도 감각 조정용 향료 조성물, 감각 조정용 물품 및 감각조정 방법과 향료 맵 |
| US20060010010A1 (en) * | 2004-07-12 | 2006-01-12 | Benjamin Wiegand | Method for recommending an acne treatment/prevention program |
| US20060008484A1 (en) * | 2004-07-12 | 2006-01-12 | Benjamin Wiegand | Acne profile |
| JP5372739B2 (ja) * | 2007-03-06 | 2013-12-18 | ライフケア技研株式会社 | 哺乳動物用ストレス測定具 |
| US10444213B2 (en) | 2016-08-25 | 2019-10-15 | Viavi Solutions Inc. | Spectroscopic classification of conformance with dietary restrictions |
| RU2697655C1 (ru) * | 2018-11-14 | 2019-08-16 | федеральное государственное бюджетное образовательное учреждение высшего образования "Новгородский государственный университет имени Ярослава Мудрого" | Способ моделирования хронического эмоционально-информационного стресса в эксперименте |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789169A (en) * | 1994-11-03 | 1998-08-04 | Regents Of The University Of California | Methods for the diagnosis of glaucoma |
| US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
| JPH1119076A (ja) * | 1997-07-07 | 1999-01-26 | Pola Chem Ind Inc | 香りの抗ストレス効果の測定法 |
| JPH1123579A (ja) * | 1997-07-07 | 1999-01-29 | Pola Chem Ind Inc | マッサージの評価方法 |
| WO1999031511A1 (en) * | 1997-12-17 | 1999-06-24 | Stichting Instituut Voor Dierhouderij En Diergezondheid | Immunoassay for hormone detection |
| JP3108765B2 (ja) * | 1999-03-24 | 2000-11-13 | 工業技術院長 | 慢性ストレス判定方法及びその装置、記録媒体、判定シート |
| US6359010B1 (en) * | 1999-11-23 | 2002-03-19 | Thomas D. Geracioti, Jr. | Methods of treating anxiety and mood disorders with oleamide |
| US6428466B1 (en) * | 2001-02-14 | 2002-08-06 | Simulated Environment Concepts, Inc. | Spa capsule |
-
2001
- 2001-12-07 US US10/012,626 patent/US20020090664A1/en not_active Abandoned
- 2001-12-20 CA CA002432167A patent/CA2432167A1/en not_active Abandoned
- 2001-12-20 WO PCT/US2001/050220 patent/WO2002062198A2/en not_active Application Discontinuation
- 2001-12-20 KR KR10-2003-7008278A patent/KR20030086246A/ko not_active Application Discontinuation
- 2001-12-20 MX MXPA03005747A patent/MXPA03005747A/es not_active Application Discontinuation
- 2001-12-20 CN CNA018221769A patent/CN1486426A/zh active Pending
- 2001-12-20 JP JP2002562209A patent/JP2005506516A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Effects of forest bathing on cardiovascular and metabolic parameters in middle-aged males | |
| Goldey et al. | Sexual thoughts: Links to testosterone and cortisol in men | |
| Rothe et al. | Examination of peripheral basal and reactive cortisol levels in major depressive disorder and the burnout syndrome: A systematic review | |
| Sinha et al. | Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states | |
| Koray et al. | The evaluation of anxiety and salivary cortisol levels in patients with oral lichen planus | |
| Kudielka et al. | Human models in acute and chronic stress: assessing determinants of individual hypothalamus–pituitary–adrenal axis activity and reactivity | |
| Rein et al. | The physiological and psychological effects of compassion and anger | |
| Almela et al. | Salivary alpha-amylase response to acute psychosocial stress: the impact of age | |
| Bost et al. | The effectiveness of a 15 minute weekly massage in reducing physical and psychological stress in nurses | |
| Master et al. | Neurobiological correlates of coping through emotional approach | |
| US20070275102A9 (en) | Method of affecting sleep and sleep-related behaviors | |
| Yoon et al. | Salivary biomarkers of neural hypervigilance in trauma-exposed women | |
| Bell et al. | Time-dependent sensitization of heart rate and blood pressure over multiple laboratory sessions in elderly individuals with chemical odor intolerance | |
| JP2005506516A5 (US20070275102A9-20071129-P00001.png) | ||
| JP2005506516A (ja) | 哺乳類動物におけるストレスを測定するための方法 | |
| Miller et al. | Diurnal variation of the startle reflex in relation to HPA‐axis activity in humans | |
| Woods et al. | Arousal and stress response across the menstrual cycle in women with three perimenstrual symptom patterns | |
| US20020146469A1 (en) | Methods for reducing chronic stress in mammals | |
| Evans et al. | Cortisol levels in children of parents with a substance use disorder | |
| Goodin et al. | Enhanced cortisol increase upon awakening is associated with greater pain ratings but not salivary cortisol or soluble tumor necrosis factor-α receptor II responses to acute pain | |
| Kunstmann et al. | Testosterone levels and stress in women: the role of stress coping strategies, anxiety and sex role identification | |
| Ragonesi et al. | Physiological responses to violence reported in the news | |
| AU2002246821A1 (en) | Methods for measuring stress in mammals | |
| EP1360506A2 (en) | Methods for measuring stress in mammals | |
| Kunati et al. | Effect of Heartfulness Meditation on Cortisol Levels and Vital Parameters in Healthy Female Medical StudentsA Prospective Longitudinal Study |